Tectonic Therapeutic (TECX) Financials

$22.58 -1.98 (-8.06%)

Closing price 04:00 PM Eastern

Extended Trading

$22.59 +0.01 (+0.04%)

As of 07:32 PM Eastern

Annual Income Statements for Tectonic Therapeutic

This table shows Tectonic Therapeutic's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-58	-43	-106
Consolidated Net Income / (Loss)	-58	-43	-106
Net Income / (Loss) Continuing Operations	-58	-43	-106
Total Pre-Tax Income	-58	-43	-106
Total Operating Income	-58	-45	-105
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	58	45	105
Selling, General & Admin Expense	17	7.68	33
Research & Development Expense	41	37	72
Total Other Income / (Expense), net	0.03	2.08	-0.46
Interest Expense	0.11	0.15	-
Interest & Investment Income	4.26	0.58	-0.30
Other Income / (Expense), net	-4.12	1.65	-0.16
Other Gains / (Losses), net	0.03	-	-
Basic Earnings per Share	($6.83)	($33.76)	($2.42)
Weighted Average Basic Shares Outstanding	8.49M	1.27M	43.74M
Diluted Earnings per Share	($6.83)	($33.76)	($2.42)
Weighted Average Diluted Shares Outstanding	8.49M	1.27M	43.74M
Weighted Average Basic & Diluted Shares Outstanding	18.66M	44.86M	44.09M
Cash Dividends to Common per Share	$0.00	-	-

This table shows Tectonic Therapeutic's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-21	-18	-13	-6.81	2.64	-10	-10	-25	-25	-23
Consolidated Net Income / (Loss)	-21	-18	-13	-6.81	2.64	-10	-10	-25	-25	-23
Net Income / (Loss) Continuing Operations	-21	-18	-13	-6.81	2.84	-9.99	-10	-25	-25	-23
Total Pre-Tax Income	-21	-18	-13	-6.81	2.90	-10	-10	-25	-25	-23
Total Operating Income	-19	-20	-11	-7.94	1.32	-10	-11	-25	-25	-23
Total Operating Expenses	19	20	11	7.94	-1.32	10	11	25	25	23
Selling, General & Admin Expense	-0.27	5.32	4.35	7.26	-4.05	1.98	1.87	7.89	7.12	7.07
Research & Development Expense	19	14	7.07	0.68	2.73	8.13	8.77	17	18	16
Total Other Income / (Expense), net	-1.77	1.92	-1.25	1.13	1.58	0.06	0.18	0.26	0.22	0.02
Interest & Investment Income	0.85	1.95	0.32	1.15	0.01	0.10	0.22	0.25	0.25	0.11
Other Income / (Expense), net	-2.56	-0.01	-1.54	-0.01	1.65	-0.00	-0.01	0.02	-0.02	-0.10
Basic Earnings per Share	($2.45)	($1.20)	($4.34)	($0.15)	$2.08	($7.62)	($8.51)	($0.57)	($0.57)	($0.52)
Weighted Average Basic Shares Outstanding	8.49M	14.73M	2.92M	44.79M	1.27M	1.32M	1.23M	44.04M	43.74M	43.77M
Diluted Earnings per Share	($2.45)	($1.20)	($4.34)	($0.15)	$2.08	($7.62)	($8.51)	($0.57)	($0.57)	($0.52)
Weighted Average Diluted Shares Outstanding	8.49M	14.73M	2.92M	44.79M	1.27M	1.32M	1.23M	44.04M	43.74M	43.77M
Basic & Diluted Earnings per Share	($2.45)	-	-	-	$2.08	-	-	-	($0.57)	-
Weighted Average Basic & Diluted Shares Outstanding	18.66M	14.75M	14.73M	44.89M	44.86M	44.57M	44.53M	44.11M	44.09M	43.77M

This table details how cash moves in and out of Tectonic Therapeutic's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	112	-7.20	-97
Net Cash From Operating Activities	-59	-41	-97
Net Cash From Continuing Operating Activities	-59	-41	-97
Net Income / (Loss) Continuing Operations	-58	-43	-106
Consolidated Net Income / (Loss)	-58	-43	-106
Depreciation Expense	1.65	1.48	1.44
Non-Cash Adjustments To Reconcile Net Income	7.54	1.25	15
Changes in Operating Assets and Liabilities, net	-10	-0.58	-7.40
Net Cash From Investing Activities	-0.16	-0.28	-0.27
Net Cash From Continuing Investing Activities	-0.16	-0.28	-0.27
Purchase of Property, Plant & Equipment	-0.16	-0.28	-0.27
Net Cash From Financing Activities	172	34	0.26
Net Cash From Continuing Financing Activities	172	34	0.26
Repayment of Debt	-0.48	34	0.00
Repurchase of Common Equity	0.00	0.00	-
Other Financing Activities, net	172	0.12	0.06
Effect of Exchange Rate Changes	-0.01	0.02	-
Cash Interest Paid	0.11	0.15	1.43

This table details how cash moves in and out of Tectonic Therapeutic's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-18	-26	164	-7.54	22	-8.60	-0.80	-20	-24	-16
Net Cash From Operating Activities	-17	-20	-15	-7.57	-12	-8.48	-0.26	-20	-24	-16
Net Cash From Continuing Operating Activities	-17	-20	-15	-7.57	-12	-8.48	-0.26	-20	-24	-16
Net Income / (Loss) Continuing Operations	-12	-18	-21	-6.81	-7.87	-10	0.06	-25	-25	-23
Consolidated Net Income / (Loss)	-12	-18	-21	-6.81	-7.87	-10	0.06	-25	-25	-23
Depreciation Expense	0.51	0.42	0.71	0.00	0.37	0.37	0.41	0.33	0.34	0.35
Non-Cash Adjustments To Reconcile Net Income	0.65	1.96	3.73	1.20	-0.41	0.56	-2.10	3.20	5.18	2.71
Changes in Operating Assets and Liabilities, net	-5.60	-4.27	1.56	-1.96	-3.75	0.65	1.38	1.14	-4.26	3.53
Net Cash From Investing Activities	-0.00	-0.15	-	0.00	-0.05	-0.01	-0.21	-0.01	-	-0.09
Net Cash From Continuing Investing Activities	-0.00	-0.15	-	0.00	-0.05	-0.01	-0.21	-0.01	-	-0.09
Purchase of Property, Plant & Equipment	-0.00	-0.15	-	0.00	-0.05	-0.01	-0.21	-0.01	-	-0.09
Net Cash From Financing Activities	-1.07	-6.29	179	0.03	34	-0.11	-0.32	0.06	0.06	0.06
Net Cash From Continuing Financing Activities	-1.07	-6.29	179	0.03	34	-0.11	-0.32	0.06	0.06	0.06
Repayment of Debt	-0.12	-0.12	-	-	34	-0.11	-	-	-	-
Repurchase of Common Equity	7.41	-6.24	-	-	-	-	-	-	-	-
Other Financing Activities, net	-8.37	0.08	180	0.03	0.12	-	-0.04	0.04	0.06	-
Effect of Exchange Rate Changes	0.04	0.02	-	-	0.02	-	-	-	-	-
Cash Interest Paid	0.05	-	0.06	0.00	0.03	0.04	-0.38	0.46	0.42	0.37

This table presents Tectonic Therapeutic's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	153	39	104
Total Current Assets	147	31	100
Cash & Equivalents	141	29	93
Prepaid Expenses	5.62	2.12	7.11
Plant, Property, & Equipment, net	2.15	3.12	2.89
Total Noncurrent Assets	3.90	5.39	1.10
Noncurrent Note & Lease Receivables	0.92	1.44	-
Other Noncurrent Operating Assets	2.98	3.96	1.10
Total Liabilities & Shareholders' Equity	153	39	104
Total Liabilities	12	43	29
Total Current Liabilities	12	41	13
Accounts Payable	0.98	0.41	0.38
Accrued Expenses	7.85	8.14	12
Other Current Liabilities	2.78	32	1.00
Total Noncurrent Liabilities	0.52	2.52	15
Other Noncurrent Operating Liabilities	0.52	2.52	0.19
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	81	-
Total Equity & Noncontrolling Interests	141	-85	75
Total Preferred & Common Equity	141	-85	75
Preferred Stock	0.00	0.00	0.00
Total Common Equity	141	-85	75
Common Stock	289	5.98	565
Retained Earnings	-149	-91	-489
Accumulated Other Comprehensive Income / (Loss)	0.01	-0.01	-

This table presents Tectonic Therapeutic's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	169	194	92	111	134	83	129
Total Current Assets	163	187	92	109	129	77	126
Cash & Equivalents	159	185	90	106	125	72	116
Prepaid Expenses	3.50	2.26	1.07	2.86	3.87	4.93	9.77
Plant, Property, & Equipment, net	2.55	2.64	0.00	0.00	2.29	2.57	3.22
Total Noncurrent Assets	3.57	3.88	0.51	1.35	2.71	3.18	0.04
Noncurrent Note & Lease Receivables	1.03	2.08	-	-	-	-	-
Other Noncurrent Operating Assets	2.54	1.81	0.51	1.35	2.71	3.18	0.04
Total Liabilities & Shareholders' Equity	169	194	92	111	134	83	129
Total Liabilities	18	28	3.51	7.66	12	30	31
Total Current Liabilities	17	26	3.51	7.56	12	14	16
Accounts Payable	2.64	4.09	0.24	0.91	1.07	0.59	1.81
Accrued Expenses	13	20	3.04	5.00	8.34	11	14
Other Current Liabilities	1.95	1.90	0.22	1.65	2.25	2.63	-
Total Noncurrent Liabilities	1.04	1.54	0.00	0.11	0.13	16	15
Other Noncurrent Operating Liabilities	1.04	1.54	-	0.11	0.13	0.35	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	-	-	-	-	-
Total Equity & Noncontrolling Interests	150	166	89	103	122	53	98
Total Preferred & Common Equity	150	166	89	103	122	53	98
Preferred Stock	0.00	-	0.00	-	-	-	-
Total Common Equity	150	166	89	103	122	53	98
Common Stock	287	285	573	571	569	567	562
Retained Earnings	-136	-118	-484	-468	-447	-514	-464
Accumulated Other Comprehensive Income / (Loss)	-0.08	-0.06	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Tectonic Therapeutic's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-45.69%	60.14%	11.36%
EBIT Growth	-44.51%	59.28%	11.19%
NOPAT Growth	-29.94%	57.65%	11.28%
Net Income Growth	-35.40%	59.56%	11.11%
EPS Growth	79.77%	59.56%	12.95%
Operating Cash Flow Growth	-45.23%	58.15%	0.83%
Free Cash Flow Firm Growth	-10,694.18%	99.12%	7.95%
Invested Capital Growth	98.59%	-1,389.91%	57.25%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-474.26%	40.52%	2.44%
EBIT Q/Q Growth	-500.52%	39.64%	2.50%
NOPAT Q/Q Growth	-336.69%	37.31%	2.50%
Net Income Q/Q Growth	-383.85%	39.26%	2.93%
EPS Q/Q Growth	-591.37%	39.26%	2.81%
Operating Cash Flow Q/Q Growth	22.70%	22.80%	2.24%
Free Cash Flow Firm Q/Q Growth	-422.32%	98.64%	4.46%
Invested Capital Q/Q Growth	94.70%	-903.31%	30.49%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.60%	100.00%
Interest Burden Percent	93.31%	99.00%	100.28%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-84.79%	-120.02%	-86.50%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-34.80%	15.58%	-86.50%
Return on Equity Simple (ROE_SIMPLE)	-41.19%	50.60%	-140.49%
Net Operating Profit after Tax (NOPAT)	-41	-31	-74
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-20.44%	-21.76%	-25.45%
Return On Investment Capital (ROIC_SIMPLE)	-28.85%	36.93%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-62	-43	-106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-60	-42	-104
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.84	0.00	4.97
Price to Tangible Book Value (P/TBV)	4.84	0.00	4.97
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.20
Long-Term Debt to Equity	0.00	0.00	0.20
Financial Leverage	-1.24	-1.49	-1.03
Leverage Ratio	1.41	2.01	1.26
Compound Leverage Factor	1.31	1.99	1.26
Debt to Total Capital	0.00%	0.00%	16.85%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	16.85%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-2,011.15%	0.00%
Common Equity to Total Capital	100.00%	2,111.15%	83.15%
Debt to EBITDA	0.00	0.00	-0.15
Net Debt to EBITDA	0.00	0.00	0.74
Long-Term Debt to EBITDA	0.00	0.00	-0.15
Debt to NOPAT	0.00	0.00	-0.21
Net Debt to NOPAT	0.00	0.00	1.05
Long-Term Debt to NOPAT	0.00	0.00	-0.21
Altman Z-Score	32.05	2.93	-1.08
Noncontrolling Interest Sharing Ratio	58.95%	112.98%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	12.65	0.76	7.62
Quick Ratio	12.17	0.70	7.06
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-73	-0.68	-77
Operating Cash Flow to CapEx	-37,871.79%	-14,581.00%	-36,407.49%
Free Cash Flow to Firm to Interest Expense	-681.55	-4.44	0.00
Operating Cash Flow to Interest Expense	-552.15	-267.64	0.00
Operating Cash Flow Less CapEx to Interest Expense	-553.61	-269.47	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-0.46	-33	-2.20
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	32	-31	2.95
Enterprise Value (EV)	540	779	297
Market Capitalization	681	727	374
Book Value per Share	$9.54	($1.90)	$1.72
Tangible Book Value per Share	$9.54	($1.90)	$1.72
Total Capital	141	-4.01	91
Total Debt	0.00	0.00	15
Total Long-Term Debt	0.00	0.00	15
Net Debt	-141	-29	-78
Capital Expenditures (CapEx)	0.16	0.28	0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.99	-39	-6.00
Debt-free Net Working Capital (DFNWC)	135	-10	87
Net Working Capital (NWC)	135	-10	87
Net Nonoperating Expense (NNE)	17	12	32
Net Nonoperating Obligations (NNO)	-141	-29	-78
Total Depreciation and Amortization (D&A)	1.65	1.48	1.44
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($6.83)	$3.24	($29.04)
Adjusted Weighted Average Basic Shares Outstanding	8.49M	3.69M	3.64M
Adjusted Diluted Earnings per Share	($6.83)	$3.24	($29.04)
Adjusted Weighted Average Diluted Shares Outstanding	8.49M	3.71M	3.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	18.66M	3.74M	3.67M
Normalized Net Operating Profit after Tax (NOPAT)	-41	-31	-74
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-580.71	-282.88	0.00
NOPAT to Interest Expense	-379.54	-205.62	0.00
EBIT Less CapEx to Interest Expense	-582.17	-284.71	0.00
NOPAT Less CapEx to Interest Expense	-381.00	-207.45	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Tectonic Therapeutic's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-731.75%	-97.25%	-19.69%	68.03%	113.37%	57.13%	62.67%	14.41%	9.45%	29.51%
EBIT Growth	-828.46%	-94.21%	-21.83%	68.44%	111.72%	56.17%	61.69%	14.45%	9.66%	29.24%
NOPAT Growth	-1,110.72%	-94.16%	-7.43%	68.51%	107.45%	56.00%	61.72%	14.27%	9.67%	29.54%
Net Income Growth	-886.45%	-76.22%	-21.20%	72.72%	110.56%	56.23%	62.73%	16.34%	11.31%	29.57%
EPS Growth	-217.79%	84.25%	49.00%	73.68%	110.56%	56.23%	62.73%	16.18%	13.64%	30.67%
Operating Cash Flow Growth	-44.30%	-131.15%	-5,724.71%	62.68%	50.76%	48.33%	99.11%	27.59%	8.59%	33.87%
Free Cash Flow Firm Growth	-243.05%	-18.65%	325.66%	55.68%	254.64%	66.33%	86.62%	0.28%	-4.35%	22.40%
Invested Capital Growth	98.59%	-167.34%	-539.08%	51.54%	-1,389.91%	-3.22%	-382.76%	-14.14%	57.25%	59.42%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-9.62%	-56.92%	-53.99%	-111.54%	134.23%	4.78%	58.87%	0.27%	-9.75%	17.10%
EBIT Q/Q Growth	-9.84%	-51.56%	-62.95%	-111.54%	129.28%	4.93%	57.79%	0.29%	-9.53%	16.89%
NOPAT Q/Q Growth	3.16%	-71.94%	-43.82%	-108.06%	118.60%	4.86%	57.85%	0.15%	-9.88%	17.24%
Net Income Q/Q Growth	-17.32%	-39.82%	-86.12%	-109.85%	126.29%	3.84%	58.11%	0.31%	-8.99%	18.13%
EPS Q/Q Growth	-104.17%	72.35%	-2,793.33%	-109.62%	126.29%	3.84%	58.11%	0.00%	-9.62%	18.75%
Operating Cash Flow Q/Q Growth	14.20%	-29.95%	-99.31%	5.75%	-37.45%	-3,174.52%	98.72%	14.32%	-44.22%	43.60%
Free Cash Flow Firm Q/Q Growth	-451.11%	-205.77%	202.91%	-107.64%	557.09%	-101.16%	79.79%	16.79%	0.48%	20.06%
Invested Capital Q/Q Growth	94.70%	53.44%	-874.39%	94.13%	-903.31%	-11.31%	26.11%	-80.55%	30.49%	-404.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	91.20%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.33%	90.19%	97.76%	85.59%	97.84%	99.40%	98.27%	99.02%	99.03%	99.52%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-84.79%	16.13%	19.48%	42.73%	-120.02%	-70.17%	-69.40%	-102.99%	-86.50%	-74.80%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-34.80%	16.13%	19.48%	42.73%	15.58%	-70.17%	-69.40%	-102.99%	-86.50%	-74.80%
Return on Equity Simple (ROE_SIMPLE)	0.00%	13.59%	16.88%	34.11%	0.00%	-68.54%	-68.35%	-190.60%	0.00%	-111.21%
Net Operating Profit after Tax (NOPAT)	-13	-14	-7.99	-5.56	1.32	-7.08	-7.44	-18	-18	-16
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-8.79%	-2.99%	-3.02%	-1.69%	2.49%	-2.87%	-2.49%	-7.17%	-5.83%	-4.55%
Return On Investment Capital (ROIC_SIMPLE)	-9.46%	-	-	-	-1.56%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-22	-20	-13	-7.95	2.96	-10	-11	-25	-25	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-19	-12	-7.95	3.34	-9.74	-10	-25	-25	-23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.84	2.97	0.37	7.76	0.00	8.00	4.12	9.98	4.97	3.44
Price to Tangible Book Value (P/TBV)	4.84	2.97	0.37	7.76	0.00	8.00	4.12	9.98	4.97	3.44
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	21.86	2.19	22.74	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	4.58%	45.59%	4.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	17.78	0.00	21.64	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	18.52	0.00	21.86	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	16.75	0.00	21.78	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	12.70	0.00	23.53	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.20	0.16
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.29	0.20	0.16
Financial Leverage	-1.24	-1.05	-1.08	-1.04	-1.49	-1.03	-1.01	-1.04	-1.03	-1.04
Leverage Ratio	1.41	1.10	1.14	1.24	2.01	1.19	1.17	1.32	1.26	1.19
Compound Leverage Factor	1.35	0.99	1.11	1.06	1.97	1.19	1.15	1.30	1.24	1.18
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.47%	16.85%	13.42%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.47%	16.85%	13.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	-2,011.15%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	2,111.15%	100.00%	100.00%	77.53%	83.15%	86.58%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.15	-0.15	-0.14
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.57	0.74	0.95
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.15	-0.15	-0.14
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.22	-0.21	-0.20
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.80	1.05	1.34
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.22	-0.21	-0.20
Altman Z-Score	32.93	14.11	1.26	111.35	6.78	59.29	21.69	1.81	1.47	1.86
Noncontrolling Interest Sharing Ratio	58.95%	0.00%	0.00%	0.00%	112.98%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.65	9.39	7.21	26.17	0.76	14.44	11.05	5.40	7.62	7.80
Quick Ratio	12.17	9.19	7.12	25.79	0.70	14.00	10.69	5.06	7.06	7.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-46	-8.28	7.83	-7.61	32	-6.98	-3.47	-17	-21	-21
Operating Cash Flow to CapEx	-560,700.00%	-12,813.07%	0.00%	0.00%	-23,314.00%	-121,157.14%	-121.03%	-253,550.00%	0.00%	-19,087.21%
Free Cash Flow to Firm to Interest Expense	0.00	-331.16	279.55	0.00	0.00	-193.83	-86.72	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-784.16	-538.79	0.00	0.00	-235.58	-6.48	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-790.28	-538.79	0.00	0.00	-235.78	-11.83	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.46	-8.73	-19	-1.93	-33	-3.27	-2.94	-3.97	-2.20	-3.17
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	32	-5.47	-16	2.05	-31	-0.10	-3.97	-0.49	2.95	4.64
Enterprise Value (EV)	540	287	-124	598	779	717	378	472	297	236
Market Capitalization	681	446	62	689	727	823	503	529	374	337
Book Value per Share	$9.54	$10.20	$3.71	$1.98	($1.90)	$2.31	$2.77	$1.20	$1.72	$2.24
Tangible Book Value per Share	$9.54	$10.20	$3.71	$1.98	($1.90)	$2.31	$2.77	$1.20	$1.72	$2.24
Total Capital	141	150	166	89	-4.01	103	122	68	91	113
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15	15	15
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15	15	15
Net Debt	-141	-159	-185	-91	-29	-106	-125	-57	-78	-101
Capital Expenditures (CapEx)	0.00	0.15	0.00	0.00	0.05	0.01	0.21	0.01	0.00	0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.99	-14	-24	-2.44	-39	-4.51	-7.79	-9.37	-6.00	-6.42
Debt-free Net Working Capital (DFNWC)	135	145	161	88	-10	102	117	63	87	110
Net Working Capital (NWC)	135	145	161	88	-10	102	117	63	87	110
Net Nonoperating Expense (NNE)	7.47	3.97	4.68	1.25	-1.33	2.97	3.01	7.30	7.35	6.88
Net Nonoperating Obligations (NNO)	-141	-159	-185	-91	-29	-106	-125	-57	-78	-101
Total Depreciation and Amortization (D&A)	0.51	0.42	0.71	0.00	0.37	0.37	0.41	0.33	0.34	0.35
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.45)	($1.20)	($4.34)	($1.80)	$24.96	($5.76)	$18.36	($6.84)	($6.84)	($6.24)
Adjusted Weighted Average Basic Shares Outstanding	8.49M	14.73M	2.92M	3.73M	105.71K	3.71M	3.68M	3.67M	3.64M	3.65M
Adjusted Diluted Earnings per Share	($2.45)	($1.20)	($4.34)	($1.80)	$24.96	($5.76)	$18.24	($6.84)	($6.84)	($6.24)
Adjusted Weighted Average Diluted Shares Outstanding	8.49M	14.73M	2.92M	3.73M	105.71K	3.71M	3.69M	3.67M	3.64M	3.65M
Adjusted Basic & Diluted Earnings per Share	($2.45)	$0.00	$0.00	$0.00	$24.96	$0.00	$0.00	$0.00	($6.84)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	18.66M	14.75M	14.73M	3.74M	3.74M	3.71M	3.71M	3.68M	3.67M	3.65M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-14	-7.99	-5.56	0.92	-7.08	-7.44	-18	-18	-16
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-785.76	-462.89	0.00	0.00	-280.97	-265.98	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-549.84	-285.53	0.00	0.00	-196.66	-186.04	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-791.88	-462.89	0.00	0.00	-281.17	-271.33	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-555.96	-285.53	0.00	0.00	-196.86	-191.39	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Tectonic Therapeutic's Financials

When does Tectonic Therapeutic's financial year end?

According to the most recent income statement we have on file, Tectonic Therapeutic's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Tectonic Therapeutic's net income changed over the last 2 years?

Tectonic Therapeutic's net income appears to be on a downward trend, with a most recent value of -$57.98 million in 2024, falling from -$105.89 million in 2022. The previous period was -$42.82 million in 2023. Find out what analysts predict for Tectonic Therapeutic in the coming months.

What is Tectonic Therapeutic's operating income?

Tectonic Therapeutic's total operating income in 2024 was -$58.02 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $58.02 million

How has Tectonic Therapeutic revenue changed over the last 2 years?

Over the last 2 years, Tectonic Therapeutic's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Tectonic Therapeutic have?

Tectonic Therapeutic's total liabilities were at $12.13 million at the end of 2024, a 72.1% decrease from 2023, and a 57.6% decrease since 2022.

How much cash does Tectonic Therapeutic have?

In the past 2 years, Tectonic Therapeutic's cash and equivalents has ranged from $28.77 million in 2023 to $141.24 million in 2024, and is currently $141.24 million as of their latest financial filing in 2024.

How has Tectonic Therapeutic's book value per share changed over the last 2 years?

Over the last 2 years, Tectonic Therapeutic's book value per share changed from 1.72 in 2022 to 9.54 in 2024, a change of 454.2%.

Related Companies

This page (NASDAQ:TECX) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Financials

Frequently Asked Questions About Tectonic Therapeutic's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Financials

Annual Income Statements for Tectonic Therapeutic

Quarterly Income Statements for Tectonic Therapeutic

Annual Cash Flow Statements for Tectonic Therapeutic

Quarterly Cash Flow Statements for Tectonic Therapeutic

Annual Balance Sheets for Tectonic Therapeutic

Quarterly Balance Sheets for Tectonic Therapeutic

Annual Metrics And Ratios for Tectonic Therapeutic

Quarterly Metrics And Ratios for Tectonic Therapeutic

Frequently Asked Questions About Tectonic Therapeutic's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools